Discovery and Optimization of Small-Molecule Ligands for V-domain Ig Suppressor of T-cell Activation (VISTA).
暂无分享,去创建一个
[1] Lieping Chen,et al. Structural insight into T cell coinhibition by PD-1H (VISTA) , 2020, Proceedings of the National Academy of Sciences.
[2] A. Yamniuk,et al. VISTA is an acidic pH-selective ligand for PSGL-1 , 2019, Nature.
[3] Po-Ssu Huang,et al. Structure and Functional Binding Epitope of V-domain Ig Suppressor of T Cell Activation. , 2019, Cell reports.
[4] J. D'haese,et al. Advances in cancer immunotherapy 2019 – latest trends , 2019, Journal of Experimental & Clinical Cancer Research.
[5] T. Holak,et al. CA-170 – A Potent Small-Molecule PD-L1 Inhibitor or Not? , 2019, bioRxiv.
[6] Lukás Jendele,et al. PrankWeb: a web server for ligand binding site prediction and visualization , 2019, Nucleic Acids Res..
[7] C. Iacobuzio-Donahue,et al. Comparison of immune infiltrates in melanoma and pancreatic cancer highlights VISTA as a potential target in pancreatic cancer , 2019, Proceedings of the National Academy of Sciences.
[8] Jun Yu Li,et al. VSIG‐3 as a ligand of VISTA inhibits human T‐cell function , 2018, Immunology.
[9] Longqin Hu,et al. Immunomodulators targeting the PD‐1/PD‐L1 protein‐protein interaction: From antibodies to small molecules , 2018, Medicinal research reviews.
[10] J. Chisholm,et al. The Next Generation of Immunotherapy for Cancer: Small Molecules Could Make Big Waves , 2019, The Journal of Immunology.
[11] N. Matsumura,et al. VISTA expressed in tumour cells regulates T cell function , 2018, British Journal of Cancer.
[12] Lieping Chen,et al. A Paradigm Shift in Cancer Immunotherapy: From Enhancement to Normalization , 2018, Cell.
[13] Hongming Zhang,et al. Current status and future directions of cancer immunotherapy , 2018, Journal of Cancer.
[14] S. Malarkannan,et al. The structure, expression, and multifaceted role of immune-checkpoint protein VISTA as a critical regulator of anti-tumor immunity, autoimmunity, and inflammation , 2018, Cellular & Molecular Immunology.
[15] G. De Velasco,et al. Analysis of response rate with ANTI PD1/PD-L1 monoclonal antibodies in advanced solid tumors: a meta-analysis of randomized clinical trials , 2018, Oncotarget.
[16] J. Wilmott,et al. Negative immune checkpoint regulation by VISTA: a mechanism of acquired resistance to anti-PD-1 therapy in metastatic melanoma patients , 2017, Modern Pathology.
[17] I. Wistuba,et al. VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancer , 2017, Nature Medicine.
[18] J. Pin,et al. BRET and Time-resolved FRET strategy to study GPCR oligomerization: from cell lines toward native tissues , 2012, Front. Endocrin..
[19] Lieping Chen,et al. Cutting Edge: A Monoclonal Antibody Specific for the Programmed Death-1 Homolog Prevents Graft-versus-Host Disease in Mouse Models , 2011, The Journal of Immunology.
[20] David C. Gondek,et al. VISTA, a novel mouse Ig superfamily ligand that negatively regulates T cell responses , 2011, The Journal of experimental medicine.
[21] Thomas Singer,et al. The safety and side effects of monoclonal antibodies , 2010, Nature Reviews Drug Discovery.